Article Versions Notes

Pleyer L, Döhner H, Dombret H, Seymour JF, Schuh AC, Beach C, Swern AS, Burgstaller S, Stauder R, Girschikofsky M, et al. Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group. International Journal of Molecular Sciences. 2017; 18(2):415. https://doi.org/10.3390/ijms18020415

Pleyer, Lisa, Hartmut Döhner, Hervé Dombret, John F. Seymour, Andre C. Schuh, CL Beach, Arlene S. Swern, Sonja Burgstaller, Reinhard Stauder, Michael Girschikofsky, and et al. 2017. "Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group" International Journal of Molecular Sciences 18, no. 2: 415. https://doi.org/10.3390/ijms18020415

Pleyer, L., Döhner, H., Dombret, H., Seymour, J. F., Schuh, A. C., Beach, C., Swern, A. S., Burgstaller, S., Stauder, R., Girschikofsky, M., Sill, H., Schlick, K., Thaler, J., Halter, B., Machherndl Spandl, S., Zebisch, A., Pichler, A., Pfeilstöcker, M., Autzinger, E. M., ... Greil, R. (2017). Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group. International Journal of Molecular Sciences, 18(2), 415. https://doi.org/10.3390/ijms18020415